{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:41:38Z","timestamp":1794487298816,"version":"4.9.1"},"reference-count":39,"publisher":"Bentham Science Publishers Ltd.","issue":"27","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,8,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Here we report on the most recent updates on experimental drugs successfully employed\nin the treatment of the disease caused by SARS-CoV-2 coronavirus, also referred to as\nCOVID-19 (COronaVIrus Disease-19). In particular, several cases of recovered patients have\nbeen reported after being treated with lopinavir\/ritonavir [which is widely used to treat Human\nImmunodeficiency Virus (HIV) infection] in combination with the anti-flu drug oseltamivir.\nIn addition, remdesivir, which has been previously administered to Ebola virus patients,\nhas also proven effective in the U.S. against coronavirus, while antimalarial chloroquine\nand hydroxychloroquine, favipiravir and co-administered darunavir and umifenovir (in\npatient therapies) were also recently recorded as having anti-SARS-CoV-2 effects. Since the\nrecoveries\/deaths ratio in the last weeks significantly increased, especially in China, it is clear\nthat the experimental antiviral therapy, together with the availability of intensive care unit\nbeds in hospitals and rigorous government control measures, all play an important role in\ndealing with this virus. This also stresses the urgent need for the scientific community to devote\nits efforts to the development of other more specific antiviral strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200416131117","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T11:31:01Z","timestamp":1587036661000},"page":"4536-4541","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":234,"title":["SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir\/Ritonavir, Darunavir\/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-2009","authenticated-orcid":true,"given":"Michele","family":"Costanzo","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine and Medical Biotechnology, School of Medicine, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3736-9592","authenticated-orcid":true,"given":"Maria Anna Rachele","family":"De Giglio","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, University of Naples 'Federico II', Via S. Pansini 5, I-80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-2367","authenticated-orcid":true,"given":"Giovanni Nicola","family":"Roviello","sequence":"additional","affiliation":[{"name":"Instituto di Biostrutture e Bioimmagini IBB - CNR; Via Mezzocannone 16, I-80134 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20) 30260-9","author":"Wu, J.T.","unstructured":"Wu, J.T.; Leung,K.; Leung, G.M. Nowcasting and forecast-ing the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a model-ling study. Lancet. 2020, The Lancet, 395(10225),689-697. https:\/\/dx.doi.org\/10.1016\/S0140-6736(20) 30260-9 PMID: 32014114","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/s1473-3099(20) 30120-1","volume":"20(5)","author":"Dong,E.","year":"2020","unstructured":"Dong,E.; Du,H.; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 2020,20(5),533-534. https:\/\/dx.doi.org\/10.1016\/s1473-3099(20) 30120-1 PMID: 32087114","journal-title":"Lancet Infect.Dis"},{"key":"ref=3","unstructured":"HUB. Real-time map from Johns Hopkins University, Balti-more (US). 2020. Available at: https:\/\/gisanddata.maps. ar-cgis.com\/apps\/opsdashboard\/index.html#\/bda7594740fd40-299423467 (Accessed: 26 March. 2020)"},{"key":"ref=4","unstructured":"World Health Organization. WHO Director-General's open-ing remarks at the media briefing on COVID-19-11 March 2020,2020. Available at: https:\/\/www.who.int\/dg\/speeches\/ detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20) 30251-8","volume":"395(10224)","author":"Lu,R.","year":"2020","unstructured":"Lu,R.; Zhao,X.; Li,J.; Niu,P.; Yang,B.; Wu,H.; Wang,W.; Song,H.; Huang,B.; Zhu,N.; Bi,Y.; Ma,X.; Zhan,F.; Wang,L.; Hu,T.; Zhou,H.; Hu,Z.; Zhou,W.; Zhao,L.; Chen,J.; Meng,Y.; Wang,J.; Lin,Y.; Yuan,J.; Xie,Z.; Ma,J.; Liu, W.J.; Wang,D.; Xu,W.; Holmes, E.C.; Gao, G.F.; Wu,G.; Chen,W.; Shi,W.; Tan, W. Genomic characterisa-tion and epidemiology of 2019 novel coronavirus: implica-tions for virus origins and receptor binding. Lancet. 2020,395(10224),565-574. http:\/\/dx.doi.org\/10.1016\/S0140-6736(20) 30251-8 PMID: 32007145","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.25.20027953","author":"Zhang,L.","unstructured":"Zhang,L.; Yang, J.R.; Zhang,Z.; Lin, Z. Genomic varia-tions of SARS-CoV-2 suggest multiple outbreak sources of transmission. medRxiv. 2020. http:\/\/dx.doi.org\/10.1101\/2020.02.25.20027953","journal-title":"medRxiv"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1476-069X-2-15","volume":"2(1)","author":"Cui,Y.","year":"2003","unstructured":"Cui,Y.; Zhang, Z.F.; Froines,J.; Zhao,J.; Wang,H.; Yu, S.Z.; Detels, R. Air pollution and case fatality of SARS in the People\u2019s Republic of China: an ecologic study. Environ. Health. 2003,2(1),15. http:\/\/dx.doi.org\/10.1186\/1476-069X-2-15 PMID: 14629774","journal-title":"Environ.Health"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14(1)","author":"Lu,H","year":"2020","unstructured":"Lu.; H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) . Biosci. Trends. 2020,14(1),69-71. http:\/\/dx.doi.org\/10.5582\/bst.2020.01020 PMID: 31996494","journal-title":"Biosci.Trends"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0140-6736(20) 30183-5","volume":"395(10223)","author":"Huang,C.","year":"2020","unstructured":"Huang,C.; Wang,Y.; Li,X.; Ren,L.; Zhao,J.; Hu,Y.; Zhang,L.; Fan,G.; Xu,J.; Gu,X.; Cheng,Z.; Yu,T.; Xia,J.; Wei,Y.; Wu,W.; Xie,X.; Yin,W.; Li,H.; Liu,M.; Xiao,Y.; Gao,H.; Guo,L.; Xie,J.; Wang,G.; Jiang,R.; Gao,Z.; Jin,Q.; Wang,J.; Cao, B. Clinical features of pa-tients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020,395(10223),497-506. https:\/\/dx.doi.org\/10.1016\/s0140-6736(20) 30183-5 PMID: 31986264","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e13823","DOI":"10.5812\/archcid.13823","volume":"12(4)","author":"Dayer, M.R.","year":"2017","unstructured":"Dayer, M.R.; Taleb-Gassabi,S.; Dayer, M.S. Lopinavir: a potent drug against coronavirus infection: insight from mo-lecular docking study. Arch. Clin. Infect. Dis. 2017,12(4),e13823. http:\/\/dx.doi.org\/10.5812\/archcid.13823","journal-title":"Arch.Clin.Infect.Dis"},{"key":"ref=11","author":"Wang,Q.","unstructured":"Wang,Q.; Zhao,Y.; Chen,X.; Hong, A. Virtual screening of approved clinic drugs with main protease (3CLpro)  re-veals potential inhibitory effects on SARS-CoV-2; Preprints. 2020,2020030144","journal-title":"2020,2020030144"},{"key":"ref=12","author":"Chen, Y.W.","unstructured":"Chen, Y.W.; Yiu, C.B.; Wong, K.Y. Prediction of the SARS-CoV-2 (2019-nCoV). 3C-like protease (3CL pro)  structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000 Res. 2019,9,129. https:\/\/dx.doi.org\/10.12688%2Ff1000research.22457.2 PMID: 32194944"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"109652","DOI":"10.1016\/j.biopha.2019.109652","volume":"121","author":"Ji,S.","year":"2020","unstructured":"Ji,S.; Bai,Q.; Wu,X.; Zhang, D.W.; Wang,S.; Shen, J.L.; Fei, G.H. Unique synergistic antiviral effects of Shufeng Jiedu capsule and oseltamivir in influenza. A viral-induced acute exacerbation of chronic obstructive pulmonary dis-ease. Biomed. Pharmacother. 2020,121,109652. http:\/\/dx.doi.org\/10.1016\/j.biopha.2019.109652 PMID: 31734578","journal-title":"Biomed.Pharmacother"},{"key":"ref=14","unstructured":"New Straits Times. Thailand sees apparent success treating coronavirus with HIV drug. 2020. Available at: https:\/\/www.nst.com.my\/world\/world\/2020\/02\/562079\/thailand-sees-apparent-success-treating-coronavirus-hiv-drug"},{"key":"ref=15","unstructured":"Sciencemag. WHO launches global megatrial of the four most promising coronavirus treatments. 2020. Available at: https:\/\/www.sciencemag.org\/news\/2020\/03\/who-launches-global-megatrial-four-most-promising-coronavirus-treatments"},{"key":"ref=16","unstructured":"News. Coronavirus experts explain the symptoms, how it spreads and how to prevent the disease. 2020. Available at: https:\/\/www.abc.net.au\/news\/2020-01-28\/coronavirus-symptoms-how-it-spreads-and-how-to-prevent-it\/11904062"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30(3)","author":"Wang,M.","year":"2020","unstructured":"Wang,M.; Cao,R.; Zhang,L.; Yang,X.; Liu,J.; Xu,M.; Shi,Z.; Hu,Z.; Zhong,W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV)  in vitro. Cell Res. 2020,30(3),269-271. http:\/\/dx.doi.org\/10.1038\/s41422-020-0282-0 PMID: 32020029","journal-title":"Cell Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","volume":"17(10)","author":"Hoenen,T.","year":"2019","unstructured":"Hoenen,T.; Groseth,A.; Feldmann, H. Therapeutic strate-gies to target the Ebola virus life cycle. Nat. Rev. Microbiol. 2019,17(10),593-606. http:\/\/dx.doi.org\/10.1038\/s41579-019-0233-2 PMID: 31341272","journal-title":"Nat.Rev.Microbiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ijantimicag.2017.05.011","volume":"50(4)","author":"Salman,S.","year":"2017","unstructured":"Salman,S.; Baiwog,F.; Page-Sharp,M.; Kose,K.; Karuna-jeewa, H.A.; Mueller,I.; Rogerson, S.J.; Siba, P.M.; Ilett, K.F.; Davis, T.M.E. Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacoki-netic modelling. Int, J. Antimicrob. Agents. 2017,50(4),542-551. http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2017.05.011 PMID: 28669839","journal-title":"Int, J.Antimicrob.Agents"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","volume":"55(5)","author":"Devaux, C.A.","year":"2020","unstructured":"Devaux, C.A.; Rolain, J.M.; Colson,P.; Raoult, D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int, J. Antimi-crob. Agents. 2020,55(5),105938. http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2020.105938 PMID: 32171740","journal-title":"Antimi-crob.Agents"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237","author":"Yao,X","unstructured":"Yao.; X. Ye,F.; Zhang,M.; Cui,C.; Huang,B.; Niu,P.; Liu,X.; Zhao,L.; Dong,E.; Song,C.; Zhan,S.; Lu,R.; Li,H.; Tan,W.; Liu, D In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) . Clin. Infect. Dis. 2020, ciaa237. https:\/\/dx.doi.org\/10.1093\/cid\/ciaa237 PMID: 32150618","journal-title":"Clin.Infect.Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"Liu,J.","year":"2020","unstructured":"Liu,J.; Cao,R.; Xu,M.; Wang,X.; Zhang,H.; Hu,H.; Li,Y.; Hu,Z.; Zhong,W.; Wang, M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020,6,16. http:\/\/dx.doi.org\/10.1038\/s41421-020-0156-0 PMID: 32194981","journal-title":"Cell Discov"},{"key":"ref=23","unstructured":"The Mainichi. Development of coronavirus treatment ad-vancing in Japan with existing meds. 2020. Available at: https:\/\/mainichi.jp\/english\/articles\/20200317\/p2a\/00m\/0na\/"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","author":"Gautret,P.","unstructured":"Gautret,P.; Lagier, J.C.; Parola,P.; Hoang, V.T.; Meddeb,L.; Mailhe,M.; Doudier,B.; Courjon,J.; Giordanengo,V.; Vieira, V.E.; Dupont, H.T.; Honor\u00e9, S.; Colson,P.; Chabri\u00e8re,E.; La Scola,B.; Rolain, J.M.; Brouqui,P.; Raoult, D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int, J. Antimicrob. Agents. 2020,105949. http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2020.105949 PMID: 32205204","journal-title":"Int, J.Antimicrob.Agents"},{"key":"ref=25","unstructured":"Chinese Clinical Trial Register (ChiCTR) . Hydroxychloro-quine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial. 2015. Available at: http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=49524"},{"key":"ref=26","unstructured":"Interim Clinical Guidance For Patients Suspected Of\/Confirmed With Covid-19 In Belgium. 2020. Available at: https:\/\/epidemio.wiv isp.be\/ID\/Documents\/Covid19\/ COVID-19_InterimGuidelines_Treatment_ENG.pdf? fbclid=IwAR2PP0GEhBHm2m3z H7c-OYFW5kksK3CG6TC40y8em3Z1QVjQ-WNxEWUTyqE"},{"key":"ref=27","unstructured":"AIFA (Agenzia Italiana del Farmaco) . Azioni intraprese per favorire la ricerca e l\u2019accesso ai nuovi farmaci per il trat-tamento del COVID-19,2020. Available at: https:\/\/www.aifa.gov.it\/-\/azioni-intraprese-per-favorire-la-ricerca-e-l-accesso-ai-nuovi-farmaci-per-il-trattamento-del-covid-19"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"105933","DOI":"10.1016\/j.ijantimicag.2020.105933","volume":"55(4)","author":"Ko, W.C.","year":"2020","unstructured":"Ko, W.C.; Rolain, J.M.; Lee, N.Y.; Chen, P.L.; Huang, C.T.; Lee, P.I.; Hsueh, P.R. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int, J. Antimicrob. Agents. 2020,55(4),105933. https:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2020.105933 PMID: 32147516","journal-title":"Int, J.Antimicrob.Agents"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMoa2001191","volume":"382(10)","author":"Holshue, M.L.","year":"2020","unstructured":"Holshue, M.L.; DeBolt,C.; Li-ndquist,S.; Lofy, K.H.; Wi-esman,J.; Bruce,H.; Spitters,C.; Ericson,K.; Wilkerson,S.; Tural,A.; Diaz,G.; Cohn,A.; Fox,L.; Patel,A.; Gerber, S.I.; Kim,L.; Tong,S.; Lu,X.; Lindstrom,S.; Pallansch, M.A.; Weldon, W.C.; Biggs, H.M.; Uyeki, T.M.; Pillai, S.K. First Case of 2019 novel coronavirus in the United States, N. Engl, J. Med. 2020,382(10),929-936. http:\/\/dx.doi.org\/10.1056\/NEJMoa2001191 PMID: 32004427","journal-title":"Engl, J.Med"},{"key":"ref=30","unstructured":"Gilead Company News And Press. Gilead Sciences State-ment on the Company\u2019s Ongoing Response to the 2019 Novel Coronavirus(2019-nCoV\/SARS-CoV-2),2019. Avail-able at: https:\/\/www.gilead.com\/news-and-press\/company-statements\/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-new-coronavirus"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1093\/jac\/dkx289","volume":"72(12)","author":"Ramos-Mart\u00edn,V.","year":"2017","unstructured":"Ramos-Mart\u00edn,V.; Johnson,A.; McEntee,L.; Farrington,N.; Padmore,K.; Cojutti,P.; Pea,F.; Neely, M.N.; Hope, W.W. Pharmacodynamics of teicoplanin against MRSA. J. Antimicrob. Chemother. 2017,72(12),3382-3389. http:\/\/dx.doi.org\/10.1093\/jac\/dkx289 PMID: 28962026","journal-title":"J.Antimicrob.Chemother"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105944","author":"Baron, S.A.","unstructured":"Baron, S.A.; Devaux,C.; Colson,P.; Raoult,D.; Rolain, J.M. Teicoplanin: an alternative drug for the treatment of COVID-19? Int, J. Antimicrob. Agents. 2020,55(4) 105944 http:\/\/dx.doi.org\/10.1016\/j.ijantimicag.2020.105944 PMID: 32179150","journal-title":"Antimicrob.Agents"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14(1)","author":"Dong,L.","year":"2020","unstructured":"Dong,L.; Hu,S.; Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19) . Drug Discov. Ther. 2020,14(1),58-60. http:\/\/dx.doi.org\/10.5582\/ddt.2020.01012 PMID: 32147628","journal-title":"Drug Discov.Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1017\/dmp.2014.151","volume":"9(1)","author":"Nagata,T.","year":"2015","unstructured":"Nagata,T.; Lefor, A.K.; Hasegawa,M.; Ishii, M. Favipi-ravir: a new medication for the ebola virus disease pan-demic. Disaster Med. Public Health Prep. 2015,9(1),79-81. http:\/\/dx.doi.org\/10.1017\/dmp.2014.151 PMID: 25544306","journal-title":"Disaster Med.Public Health Prep"},{"key":"ref=35","unstructured":"Trieste All News. Coronavirus, will \u201cTocilizumab\u201d be the drug of hope?, 2020. Available at: https:\/\/www.triesteallnews.it\/2020\/03\/14\/coronavirus-will-tocilizumab-be-the-drug-of-hope\/"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.4161\/mabs.1.5.9497","volume":"1(5)","author":"Venkiteshwaran,A","year":"2009","unstructured":"Venkiteshwaran.; A. Tocilizumab. MAbs. 2009,1(5),432-438. http:\/\/dx.doi.org\/10.4161\/mabs.1.5.9497 PMID: 20065633","journal-title":"MAbs"},{"key":"ref=37","unstructured":"REUTERS (World News) . China approves use of Roche drug in battle against coronavirus complications. 2019. Available at: https:\/\/www.reuters.com\/article\/us-health-coronavirus-china-roche-hldg\/china-approves-use-of-roche-arthritis-drug-for-coronavirus-patients-idUSKBN20R0LF"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1073\/pnas.1617020114","volume":"114(2)","author":"Kadam, R.U.","year":"2017","unstructured":"Kadam, R.U.; Wilson, I.A. Structural basis of influenza virus fusion inhibition by the antiviral drug arbidol. Proc. Natl. Acad. Sci. USA. 2017,114(2),206-214. http:\/\/dx.doi.org\/10.1073\/pnas.1617020114 PMID: 28003465","journal-title":"Proc.Natl.Acad.Sci.USA"},{"key":"ref=39","unstructured":"South China Morning Post. Notice on last positive results in China with combination therapies with antiviral drugs used against. 2019. Available at: https:\/\/www.scmp.com\/ news\/china\/society\/article\/3048993\/chinese-officials-say-priority-stop-mild-coronavirus-cases"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T15:09:31Z","timestamp":1605193771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181009\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":39,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2020,8,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200416131117","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}